These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18285439)

  • 1. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
    J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
    Hughes MD
    Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
    Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
    Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective.
    Grothey A
    Stat Methods Med Res; 2008 Oct; 17(5):529-35. PubMed ID: 18285442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
    Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
    Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
    Piedbois P; Buyse M
    Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A statistical model for the dependence between progression-free survival and overall survival.
    Fleischer F; Gaschler-Markefski B; Bluhmki E
    Stat Med; 2009 Sep; 28(21):2669-86. PubMed ID: 19579225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
    Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
    J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.